1. Introduction
===============

Upper respiratory tract infection (URTI) also known as the common cold, is a common and frequent respiratory disease mainly caused by viruses ^\[[@R1],[@R2]\]^ and is typically diagnosed in physician offices^\[[@R3]\]^ or emergency rooms.^\[[@R4]\]^ Common cold symptoms include rhinitis, sore throat, rhinorrhoea, cough and malaise.^\[[@R5],[@R6]\]^ The average duration is approximately 7 days,^\[[@R7]\]^ and most cases resolve within 10 days.^\[[@R8]\]^

In the USA, antibiotics are prescribed for more than 70% of URTI outpatients.^\[[@R9]\]^ Additionally, in South Korea, the use of antibiotics for URTI is substantial, though the prescription rate of antibiotics for URTI decreased from 73.33% in 2002 to 43,73% in 2014.^\[[@R10]\]^ Inappropriate antibiotic or overuse for URTI is a contributor to antibiotic resistance, a public health threat.^\[[@R11],[@R12]\]^ Therefore, it is necessary to prevent the overuse or abuse of antibiotics for URTI. For this purpose, the administration of medications other than antibiotics that have clinical evidence of safety and efficacy for URTI and active educational intervention of the appropriate use of antibiotics in URTI should be encouraged.

Eunkyosan (EKS) is commonly used in traditional Korean medicine and traditional Chinese medicine for URTI on its own or in combination with conventional medicine (CM). EKS was first introduced in *systematic differentiation of warm pathogen diseases (Wēn Bìng Tiáo Biàn)* by Wu Tang (1798) in China during the Qing Dynasty.^\[[@R13]\]^ In clinical practice, it is spicy and cold and has detoxifying properties for turning off heat. Therefore, it is used for respiratory infections such as URTI, bronchitis and other inflammatory diseases.^\[[@R13]\]^

In contrast to its wide use in the clinical setting, the effects have been questioned because systematic reviews of randomised clinical trials of EKS have not been presented. The aim of this study was to explore the clinical efficacy and safety of EKS based on randomised controlled trials (RCTs).

2. Methods
==========

2.1. Ethical issues
-------------------

As this study did not collect any personal, sensitive or confidential information, ethical approval was not necessary.

2.2. Study registration
-----------------------

This study followed the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement for meta-analyses of healthcare interventions.^\[[@R14]\]^ The protocol for this systematic review has been registered at PROSPERO 2018 under the number CRD42018087694.

2.3. Data sources
-----------------

The following databases were searched from inception to the present: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), AMED, and CINAHL. We also searched 6 Korean medical databases (i.e., OASIS, the Korean Traditional Knowledge Portal, the Korean Studies Information Service System, KoreaMed, the Korean Medical Database and DBPIA) and 3 Chinese databases, including CNKI (i.e., the China Academic Journal, the China Doctoral Dissertations and Master\'s Theses Full-text Database, the China Proceedings of Conference Full-Text Database and the Century Journal Project), Wanfang and VIP. In addition, we searched a Japanese database and conduct non-electronic searches of conference proceedings. The search strategy applied for the MEDLINE database is presented in Supplement 1. Similar search strategies were used for the other databases.

2.4. Types of studies
---------------------

Prospective RCTs that evaluate the effectiveness of EKS for the common cold were included in this review. Both treatment with EKS alone and concurrent treatment with EKS and another therapy were considered acceptable if EKS was applied to the intervention group only and any other treatment was provided equally to both groups. Trials with any type of control intervention were included. No language restrictions were imposed. Hard copies of all articles were obtained and read in full.

2.5. Types of participants
--------------------------

All types of common colds were eligible for inclusion. Participants who had both the common cold and accompanying diseases were excluded. There were no restrictions based on other factors, such as age, sex, or symptom severity.

2.6. Types of interventions
---------------------------

Studies that evaluated any type of formulation (ie, decoction, tablet, pill, powder) of EKS were eligible for inclusion. The compositions of interventions were reviewed, and interventions involving herbal combinations that differ from original EKS from the perspective of traditional East Asian medicine were excluded from this review.

2.7. Data extraction and quality assessment
-------------------------------------------

As mentioned above, hard copies of all articles were obtained and read in full. Two authors (HL and BK) performed the data extraction and quality assessment using a predefined data extraction form. Risk of bias was assessed by another 2 authors (MH and HLL) using the Cochrane Handbook risk of bias assessment tool version 5.1.0, which considers random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias.^\[[@R15]\]^ The results of the assessments were categorised using scores of 'L', 'U', and 'H', with 'L' indicating a low risk of bias; 'U', an uncertain risk of bias; and 'H', a high risk of bias. Disagreements were resolved by discussion between all authors. When disagreements regarding selection could not be resolved through discussion, an arbiter (JAL) made the final decision.

2.8. Data collection
--------------------

### 2.8.1. Outcome measures

#### 2.8.1.1. Primary outcomes

Improved effectiveness including total treatment efficacy; that is, the number of patients whose common cold symptoms improved

#### 2.8.1.2. Secondary outcomes

Change in symptoms (e.g., fever, cough, nasal symptoms, headache)

Changes in Chinese Quality of Life Instrument (ChQoL) scores

AEs

2.9. Assessment of bias in the included studies
-----------------------------------------------

We independently assessed the bias of the included studies according to the criteria in the Cochrane Handbook, version 5.1.0; these criteria include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias.

2.10. Data synthesis
--------------------

Differences between intervention and control groups were assessed. Mean differences (MDs) with 95% confidence intervals (CIs) were used to measure the effects of treatment for continuous data. We converted other forms of data to MDs. For outcome variables on different scales, we used standard MDs (SMDs) with 95% CIs. For dichotomous data, we present treatment effects as relative risks (RRs) with 95% CIs; other binary data were converted to RR values.

All statistical analyses were conducted using Cochrane Collaboration\'s software program Review Manager (RevMan) version 5.3. (Copenhagen, The Nordic Cochrane Centre, the Cochrane Collaboration, 2012) for Windows. We contacted the corresponding authors of studies with missing information to acquire and verify data whenever possible. When appropriate, we pooled the data across studies to conduct a meta-analysis using fixed or random effects. We used GRADEpro software from Cochrane Systematic Reviews to create a summary of findings table.

2.11. Unit of analysis issues
-----------------------------

For crossover trials, data from the first treatment period were used. For trials that assessed more than 1 control group, the primary analyses were combined data from each control group. Subgroup analyses of the control groups were performed. Each patient was counted only once in the analyses.

2.12. Addressing missing data
-----------------------------

Intention-to-treat analyses including all randomised patients were performed. For patients with missing outcome data, the last observation carry-forward analysis was performed. When individual patient data were initially unavailable, we reviewed the original source or the published trial reports for these data.

2.13. Assessment of heterogeneity
---------------------------------

Based on the data analysis, we used random- or fixed-effect models to conduct the meta-analysis. Chi-squared and I-squared tests were applied to evaluate heterogeneity among the included studies, whereby I^2^ values \>50 indicated high heterogeneity. When heterogeneity was observed, subgroup analyses were conducted to explore the possible causes.^\[[@R16]\]^

2.14. Assessment of reporting biases
------------------------------------

Funnel plots were generated to detect reporting biases when a sufficient number of included studies (at least 10 trials) was available.^\[[@R17]\]^ However, as funnel plot asymmetries are not equivalent to publication biases, we aimed to determine the possible reasons for any asymmetries in the included studies, such as small-study effects, poor methodological quality and true heterogeneity.^\[[@R17],[@R18]\]^

3. Results
==========

3.1. Study selection
--------------------

The initial search identified 5536 records after duplicates (n = 621) were removed, of which 4915 full papers were identified for further examination. Records were screened, and studies were excluded on the basis of their titles and abstracts when they did not fulfil the inclusion criteria (n = 4600). After screening the full text of selected papers (n = 315), full-text articles were excluded, with the following reasons: not clinical (n = 13), not related to the common cold (n = 39), not related to EKS (n = 140), co-medication with CM (n = 35), EKS for the control group (n = 17), a thesis for a degree (n = 34), paediatric subjects (n = 32) and 1 study in 2 papers (n = 1). Ultimately, 4 studies met the inclusion criteria (Fig. [1](#F1){ref-type="fig"}).

![Flow chart of the trial selection process.](medi-99-e21415-g001){#F1}

3.2. Description of included trials
-----------------------------------

The main characteristics of the 4 included studies are presented in Table [1](#T1){ref-type="table"}.^\[[@R19]--[@R22]\]^ All of the included RCTs originated in China and were published between 2011 and 2013. The treatment periods were all 10 days, excepting follow-up days.
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3.3. Risk of bias
-----------------

The risk of bias was unclear across the several domains in the included trials (Fig. [2](#F2){ref-type="fig"}). Four trials were described as 'randomised', whereas only 1 trial reported the random sequence generation method.^\[[@R22]\]^ One study mentioned allocation concealment,^\[[@R22]\]^ and no studies reported blinding of the outcome assessment. Three studies used CM as the control.^\[[@R19]--[@R21]\]^ All trials reported the patients' baseline characteristics. None of the trials published protocols; thus, the studies had an unclear risk of bias for selective reporting of outcomes. Another risk of bias is the participant\'s number difference in the comparison group between the comparison group total from men plus women participants.^\[[@R20]\]^

![(A) Risk of bias graph: review authors' judgements about each item\'s risk of bias item presented as a percentage across all included studies. (B) Risk of bias summary: review authors' judgements about each item\'s risk of bias for each included study. +: low risk of bias; −: high risk of bias; ?: unclear.](medi-99-e21415-g003){#F2}

3.4. Outcome measurements
-------------------------

### 3.4.1. EKS alone vs CM

#### 3.4.1.1. Response rate (total symptoms)

Three RCTs examined the effects of EKS for treating the common cold compared to CM.^\[[@R19]--[@R21]\]^ Two RCTs showed superior effects of EKS on the treatment effect.^\[[@R19],[@R20]\]^ The meta-analysis revealed favourable effects of EKS on the treatment effect (n = 308, RR: 1.22, 95% CI: 1.12 to 1.32, *P* = .001, *I*^2^ = 85%, Fig. [3](#F3){ref-type="fig"}A-1).

![Forest plot of EKS versus conventional medicine for the following: response rate (total symptoms) (3A-1); time for remission of fever, hour (3A-2); time for remission of cough, hour (3A-3); time for remission of nasal symptoms, hour (3A-4); time for remission of headache, hour (3A-5). EKS versus placebo changes in symptom scores (3B-1); changes in ChQoL scores (3B-2). ChQoL = changes in the Chinese quality of life instrument, EKS = eunkyosan.](medi-99-e21415-g004){#F3}

#### 3.4.1.2. Time for remission (fever, hour)

Two RCTs explored the effects of EKS for times for remission of fever compared to CM.^\[[@R19],[@R21]\]^ Two RCTs were included in the meta-analysis. Two RCTs demonstrated superior treatment effects of EKS. The meta-analysis result was favourable for the treatment effect of EKS (n = 116, SMD: −3.03, 95% CI: −8.85 to 2.79, *I*^2^ = 99%, Fig. [3](#F3){ref-type="fig"}A-2).

#### 3.4.1.3. Time for remission (cough, hour)

Two RCTs tested the effects of EKS for times for remission of nasal symptoms compared to CM,^\[[@R19],[@R21]\]^ and two RCTs were included in the meta-analysis. Superior treatment effects of EKS were reported in 1 RCT,^\[[@R19]\]^ and the result of our meta-analysis was favorable for the treatment effect of EKS (n = 116, SMD: −0.62, 95% CI: −1.02 to −0.21, *I*^2^ = 97%, Fig. [3](#F3){ref-type="fig"}A-3).

#### 3.4.1.4. Time for remission (nasal symptoms, hour)

The effects of EKS for times for remission of nasal symptoms compared to CM were assessed in 2 RCTs.^\[[@R19],[@R21]\]^ Two RCTs were included in the meta-analysis, and 1 RCT showed superior treatment effects of EKS.^\[[@R19]\]^ The meta-analysis result was not favorable for the treatment effect of EKS (n = 116, SMD: −0.59, 95% CI: −0.97 to −0.22, *I*^2^ = 42%, Fig. [3](#F3){ref-type="fig"}A-4).

#### 3.4.1.5. Time for remission (headache, hour)

One RCT evaluated the effects of EKS for time for remission of nasal symptoms compared to CM,^\[[@R21]\]^ and it was included in the meta-analysis. However, the meta-analysis result was not favourable for the treatment effect of EKS (n = 60, SMD: −0.07, 95% CI: −0.58 to −0.43, heterogeneity: not applicable, Fig. [3](#F3){ref-type="fig"}A-5).

3.5. EKS vs Placebo
-------------------

### 3.5.1. Changes in the symptom scores

One RCT tested the effects of EKS for treating the common cold compared to placebo.^\[[@R22]\]^ It was included in the meta-analysis, which showed no valid effect of EKS on changes in symptom scores (n = 165, MD: 0.00, 95% CI: −.0.34 to 0.34, Heterogeneity: Not applicable, Fig. [3](#F3){ref-type="fig"}B-1).

### 3.5.2. Changes in ChQoL scores

One RCT was included in the meta-analysis of changes in ChQoL scores^\[[@R22]\]^ and showed no valid effect of EKS (n = 165, MD: −1.00, 95% CI: −3.15 to 1.15, Heterogeneity: Not applicable, Fig. [3](#F3){ref-type="fig"}B-2)

### 3.5.3. Adverse events (AEs)

Only 1 study addressed AEs.^\[[@R22]\]^ AEs reported for EKS were stomach-ache, thirst, sweating, stomach gas, constipation, vomiting, insomnia, frequent urine, yellow urine, productive phlegm, and itchiness. The AEs were regarded as mild symptoms.

### 3.5.4. Information related to EKS usage

Two studies reported the related TM pattern^\[[@R21],[@R22]\]^ as wind-heat syndrome, and they used the pattern as an inclusion criterion. All durations of the studies were within 10 days, excluding the follow-up duration. Four studies reported the kinds of EKS formulas, among which 2 studies reported the detailed composition of EKS.^\[[@R20],[@R21]\]^

4. Discussion
=============

The results of this systematic review and meta-analysis provide suggestive evidence of the superiority of EKS alone or combined with conventional drugs. In addition, the study results support the efficacy of EKS, which is widely used for the common cold in Asia, especially in Korea and China.^\[[@R23],[@R24]\]^ In contrast to its wide usage, evidence of the efficacy and safety of EKS has not been examined. Although some clinical study results have consistently shown that EKS is effective for the common cold, the study quality and quality of reporting were relatively low.^\[[@R19]--[@R21]\]^ Studies of EKS have revealed that EKS is effective for treating the common cold, especially wind-heat syndrome, but those studies were conducted with a small sample size, and generalisation is unclear. There is no report of the effect of EKS in a larger sample size. Its study quality and quality of reporting were relatively low. Therefore, the level of evidences was low or very low (Fig. [4](#F4){ref-type="fig"}   ).
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The study objectives and designs were of 2 kinds: EKS compared with CM and with placebo. The results of the present study suggest that the use of EKS for the common cold is more effective than CM with regard to total symptom score, remission time of nasal symptoms and remission time of cough, but with no significant difference in remission time of fever, headache or comparison with placebo. The adverse effects were not significantly different between the EKS treatment group and the placebo control group.

Relatively high heterogeneity was observed when comparing EKS with CM for the response rate (85%), time for remission of fever (99%), time for remission of cough (97%), and time for remission of nasal symptoms (42%). The reasons for the high heterogeneity are as follows: the risk of bias of each study was high, especially performance bias, and 3 studies that included EKS with CM did not have enough participants to explore actual effects.

In terms of TM theory, EKS is regarded to cure wind-heat syndrome. Wind-heat syndrome is a syndrome in which a contagion of external wind heat enters the skin, nose and mouth and causes the fluid in the lung to dry, resulting in the stagnant fluid becoming sputum, heat trapped in the lung and coughing.^\[[@R25]\]^ The clinical symptoms vary, and the main symptoms are chills and fever, cough, and sore throat.^\[[@R26]\]^

This review had several limitations. First, all the RCTs were conducted in China, and the generalisation of these results to other countries might be limited. Second, most of the trials did not use internationally recognised reliability and validity outcome measurements. The result of the response rate can be distorted by the practitioner. Future trials in compliance with international standards in the evaluation of treatment effects may resolve this issue. Another possibility is the lack of standardisation of herbal ingredients in each study. Indeed, 2 studies did not explain the exact composed herb formulas,^\[[@R19],[@R22]\]^ and in 1 study, the composition of the formula was different depending on the participant\'s symptoms.^\[[@R20]\]^ In this situation, standardisation of natural products used in clinical trials is one of the most necessary factors for demonstrating good reproducibility of the research results for real clinical practice.

Our results suggest that more studies should be conducted with a low risk of biases and heterogeneity to provide a clearer effect of EKS for the common cold.
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